The utility of anti-SOX2 antibodies for cancer prediction in patients with paraneoplastic neurological disorders.
Antibodies
Lambert-Eaton myasthenic syndrome
Paraneoplastic
SOX2
Small-cell lung cancer
Journal
Journal of neuroimmunology
ISSN: 1872-8421
Titre abrégé: J Neuroimmunol
Pays: Netherlands
ID NLM: 8109498
Informations de publication
Date de publication:
15 01 2019
15 01 2019
Historique:
received:
10
09
2018
revised:
05
11
2018
accepted:
05
11
2018
pubmed:
18
11
2018
medline:
30
11
2019
entrez:
17
11
2018
Statut:
ppublish
Résumé
Antibodies to SOXB1 proteins in patients with paraneoplastic disorders are associated with small-cell lung cancer (SCLC), particularly in Lambert-Eaton myasthenic syndrome (LEMS). We aimed to establish if SOX2 antibodies could be used to identify SCLC and other tumours found in a range of paraneoplastic disorders and controls. SOX2 antibodies were detectable in 61% of patients with LEMS-SCLC, and in other paraneoplastic disorders, such as opsoclonus-myoclonus and paraneoplastic cerebellar degeneration, only when there was an underlying SCLC. SOX2 antibodies are specific (>90%) markers for SCLC, but are rarely found in patients with other tumours, whether neurological symptoms are present or not.
Identifiants
pubmed: 30445363
pii: S0165-5728(18)30421-1
doi: 10.1016/j.jneuroim.2018.11.003
pmc: PMC6375907
pii:
doi:
Substances chimiques
Autoantibodies
0
Biomarkers, Tumor
0
SOX2 protein, human
0
SOXB1 Transcription Factors
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
14-18Informations de copyright
Copyright © 2018 Elsevier B.V. All rights reserved.
Références
Int J Mol Sci. 2011 Jan 14;12(1):410-28
pubmed: 21339995
Expert Rev Anticancer Ther. 2006 Aug;6(8):1215-23
pubmed: 16925487
Arch Neurol. 2010 Mar;67(3):330-5
pubmed: 20212230
J Neurol Sci. 2016 Oct 15;369:342-346
pubmed: 27653921
J Cancer Res Clin Oncol. 2011 Jan;137(1):131-7
pubmed: 20349085
Muscle Nerve. 2005 Oct;32(4):515-20
pubmed: 16003742
Cancer. 2005 Jun 15;103(12):2575-83
pubmed: 15880380
Oncogene. 2012 Mar 15;31(11):1354-65
pubmed: 21822303
Ann Oncol. 2010 Aug;21(8):1687-93
pubmed: 20124350
J Neuroimmunol. 2005 Aug;165(1-2):166-71
pubmed: 15949849
Neurosci Lett. 2009 Jan 30;450(2):114-6
pubmed: 19061938
Proc Natl Acad Sci U S A. 2000 Apr 11;97(8):4198-203
pubmed: 10760287
BMC Cancer. 2011 Jan 28;11:42
pubmed: 21276239
PLoS One. 2013;8(3):e60438
pubmed: 23536908
Lung Cancer. 2010 Dec;70(3):335-9
pubmed: 20371131
Mod Pathol. 2007 Jul;20(7):742-8
pubmed: 17464316
Lancet Neurol. 2013 Feb;12(2):157-65
pubmed: 23290630
Muscle Nerve. 2001 Sep;24(9):1236-8
pubmed: 11494280
J Neurol Neurosurg Psychiatry. 2004 Aug;75(8):1135-40
pubmed: 15258215
Ann Neurol. 2004 Nov;56(5):715-9
pubmed: 15468074
Pract Neurol. 2010 Oct;10(5):260-70
pubmed: 20858627
Mov Disord. 2008 Jul 30;23(10):1370-7
pubmed: 18546342
Brain. 2000 Jul;123 ( Pt 7):1481-94
pubmed: 10869059
Eur J Neurol. 2011 Jan;18(1):19-e3
pubmed: 20880069
Neurology. 2015 Jul 21;85(3):235-9
pubmed: 26109714
Lancet Neurol. 2011 Dec;10(12):1098-107
pubmed: 22094130
Am J Clin Pathol. 2009 May;131(5):731-6
pubmed: 19369635
Brain. 1988 Jun;111 ( Pt 3):577-96
pubmed: 2838124
Neuromuscul Disord. 2006 Jul;16(7):459-67
pubmed: 16793269
Clin Cancer Res. 2011 Mar 15;17(6):1474-80
pubmed: 21138858
Clin Exp Med. 2011 Dec;11(4):251-4
pubmed: 21190055
Ann Oncol. 2011 Feb;22(2):383-9
pubmed: 20675559
J Neuroimmunol. 2010 Sep 14;226(1-2):177-80
pubmed: 20701982
Dev Dyn. 2007 Aug;236(8):2356-66
pubmed: 17584862
J Clin Oncol. 2009 Sep 10;27(26):4260-7
pubmed: 19667272
J Cell Biochem. 2009 Apr 1;106(5):867-77
pubmed: 19199344
Brain. 2001 Feb;124(Pt 2):437-43
pubmed: 11157570
Neurology. 2008 Mar 18;70(12):924-8
pubmed: 18032743
Mod Pathol. 2015 Dec;28(12):1613-20
pubmed: 26564007